Memantina Rasec

Memantine, the active ingredient in Memantina Rasec, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the symptomatic treatment of moderate to severe Alzheimer’s disease in adults.

GNH USA supplies Memantina Rasec as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Memantina Rasec is used in the management of Alzheimer’s disease, a neurodegenerative disorder affecting cognition and daily function.

- Alzheimer’s disease (moderate to severe): improves cognition, global functioning and activities of daily living.

Common Side Effects: - Dizziness: mild to moderate sensation of light‑headedness. - Headache: transient, often resolves without intervention. - Constipation: reduced bowel movements, may require dietary adjustment. - Confusion: occasional disorientation or difficulty concentrating. - Hypertension: mild increase in blood pressure. - Fatigue: feeling of tiredness or reduced energy.

Serious or Rare Side Effects: - Seizures: rare occurrence, requires immediate medical attention. - Cardiac arrhythmia: irregular heart rhythm, potentially serious. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Suicidal thoughts: emergent mood changes needing urgent evaluation. - Hepatic dysfunction: abnormal liver enzymes. - Hallucinations: visual or auditory disturbances.

Memantina Rasec should be used with caution in the following situations: - Renal impairment: dose adjustment may be required. - History of seizures: monitor closely for increased frequency. - Cardiovascular disease: assess blood pressure and heart rhythm. - Concomitant NMDA antagonists: avoid additive neurotoxicity. - Pregnancy: safety not established; weigh benefits against risks. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantina Rasec may interact with several medicines. Review the following categories:

Major Interactions (Avoid): - Amantadine: additive NMDA antagonism may increase neurotoxicity. - Other NMDA antagonists: combined effect can exacerbate CNS depression. - Strong CYP3A4 inducers (e.g., rifampicin): may reduce memantine exposure.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may diminish cognitive benefit. - Diuretics: can increase risk of hypotension. - Antihypertensives: monitor blood pressure for additive effects.